Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Trial Profile

Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Teriparatide (Primary) ; Calcium; Risedronic acid; Vitamin D
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms VERO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Jan 2014 As per ClinicalTrials.gov record planned end date changed from 1 Apr 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top